[HTML][HTML] Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence
NM Almansour - Frontiers in Molecular Biosciences, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen,
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …
[HTML][HTML] Triple negative breast cancer: a review of present and future diagnostic modalities
SA Dass, KL Tan, R Selva Rajan, NF Mokhtar… - Medicina, 2021 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …
the characterization of emerging subclones, which seed metastatic sites, might offer new …
[HTML][HTML] Improved breast cancer histological grading using deep learning
Background The Nottingham histological grade (NHG) is a well-established prognostic
factor for breast cancer that is broadly used in clinical decision making. However,∼ 50% of …
factor for breast cancer that is broadly used in clinical decision making. However,∼ 50% of …
[HTML][HTML] Characteristics of triple-negative breast cancer
TC de Ruijter, J Veeck, JPJ de Hoon… - Journal of cancer …, 2011 - Springer
Background Triple-negative breast cancers (TNBC) neither express hormone receptors, nor
overexpress HER2. They are associated with poor prognosis, as defined by low five-year …
overexpress HER2. They are associated with poor prognosis, as defined by low five-year …
[HTML][HTML] Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast …
BK Linderholm, H Hellborg, U Johansson… - Annals of oncology, 2009 - Elsevier
Background Triple-negative breast cancer (TNBC) lacking expression of steroid receptors
and human epidermal growth factor receptor 2, having chemotherapy as the only …
and human epidermal growth factor receptor 2, having chemotherapy as the only …
[HTML][HTML] Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer
Triple-negative breast cancer, defined as that with negative expression of estrogen and
progesterone receptors and cerbB2, accounted for 11% of invasive breast cancers in our …
progesterone receptors and cerbB2, accounted for 11% of invasive breast cancers in our …
Triple‐negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity
F Lara‐Medina, V Pérez‐Sánchez… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Triple‐negative breast cancer (TNBC) is defined as breast cancer that is
negative for estrogen receptor, progesterone receptor, and human epidermal growth factor …
negative for estrogen receptor, progesterone receptor, and human epidermal growth factor …
[HTML][HTML] Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
Introduction Triple negative breast cancer (TNBC) has a poorer survival, despite a higher
response rate to neoadjuvant chemotherapy. The purpose of this study was to identify the …
response rate to neoadjuvant chemotherapy. The purpose of this study was to identify the …
[HTML][HTML] Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells
PMM Ozawa, F Alkhilaiwi, IJ Cavalli… - Breast Cancer Research …, 2018 - Springer
Purpose Triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, is
genetically heterogeneous which challenges the identification of clinically effective …
genetically heterogeneous which challenges the identification of clinically effective …